alanine has been researched along with Idiopathic Parkinson Disease in 130 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The non-dopaminergic and dopaminergic actions of safinamide may alleviate pain in patients with Parkinson's disease (PD)." | 9.41 | Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study. ( Hattori, N; Ishida, T; Koebis, M; Kogo, Y; Nomoto, M; Suzuki, I; Tsuboi, Y, 2021) |
| "To investigate the long-term (2-year) efficacy of safinamide on PD chronic pain and to confirm the positive effects observed after 6 months of treatment." | 9.27 | Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain. ( Castellani, P; Cattaneo, C; Kulisevsky, J; Tubazio, V, 2018) |
| "To investigate the effects of safinamide on pain management in PD patients with motor fluctuations using pooled data from studies 016 and SETTLE." | 9.24 | Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis. ( Barone, P; Bonizzoni, E; Cattaneo, C; Sardina, M, 2017) |
| "Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is often limited by wearing off effect and dyskinesias." | 9.24 | Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. ( Anand, R; Fox, SH; Hauser, RA; Jankovic, J; Jost, WH; Kenney, C; Kulisevsky, J; Pahwa, R; Poewe, W; Schapira, AH, 2017) |
| "In an open pilot study, doses of safinamide (100, 150, and 200 mg once a day, higher than previously tested) were administered to 13 parkinsonian patients along with a stable dose of dopamine (DA) agonist, causing a significant progressive improvement in motor performance as evaluated by the Unified Parkinson Disease Rating Scale (UPDRS) part III over an 8-week period (4." | 9.12 | Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. ( Battaglia, G; Cattaneo, C; De Pandis, MF; Fariello, RG; Grassini, P; Stocchi, F; Vacca, L, 2006) |
| "Merck Serono SA (formerly Serono), under license from Newron Pharmaceuticals SpA (following its acquisition of the rights from Pharmacia and Upjohn AB [now Pfizer Inc]), is developing the oral alpha-aminoamide derivative of milacemide, safinamide, a monoamine oxidase-B and glutamate release inhibitor, for the potential treatment of Parkinson's disease, epilepsy and restless legs syndrome." | 8.84 | Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. ( Chazot, PL, 2007) |
| "Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS, leading to an improvement of motor complications, mood and pain." | 8.12 | Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. ( Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M, 2022) |
| "Safinamide was well-tolerated and improved sleep and daytime sleepiness in PD patients at 6 months." | 8.12 | Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study. ( Alonso Losada, MG; Cabo López, I; Cimas Hernando, MI; Cores Bartolomé, C; Gonzalez Palmás, MJ; Labandeira Guerra, C; Martínez Miró, C; Paz González, JM; Santos García, D; Yáñez Baña, R, 2022) |
| "Our results suggest that safinamide may have a beneficial effect on pain, a key unmet need in fluctuating PD patients." | 8.02 | Effects of safinamide on pain in patients with fluctuating Parkinson's disease. ( Falkenburger, B; Grigoriou, S; Hausbrand, D; Leta, V; Martínez-Martín, P; Odin, P; Ray Chaudhuri, K; Reichmann, H; Rukavina, K, 2021) |
| "Lewy bodies are found in Parkinson disease and related disorders and are extensively phosphorylated at Ser-129 (S129), but whether S129 phosphorylation mediates alpha-synuclein aggregation and neurotoxicity has been controversial." | 7.75 | Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. ( Fan, Z; Feany, MB; Hyman, BT; McFarland, NR; McLean, PJ; Schwarzschild, MA; Xu, K, 2009) |
| "Three point mutations (A30P, E46K, and A53T) as well as gene triplication genetically link the 140-residue protein alpha-synuclein (aS) to the development of Parkinson disease." | 7.73 | Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants. ( Bax, A; Ulmer, TS, 2005) |
| "Safinamide is a monoamine oxidase B (MAOB) inhibitor that facilitates CDS." | 5.91 | The effects of safinamide on dysphagia in Parkinson's disease. ( Hirano, M; Isono, C; Nagai, Y; Samukawa, M, 2023) |
| "Pain is a common and disabling non-motor symptom (NMS) of Parkinson's disease (PD), which occurs through the course of the disease, often unrecognized and undertreated." | 5.56 | Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study. ( Bovi, T; Di Vico, IA; Geroin, C; Segatti, A; Squintani, G; Tinazzi, M, 2020) |
| "The non-dopaminergic and dopaminergic actions of safinamide may alleviate pain in patients with Parkinson's disease (PD)." | 5.41 | Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study. ( Hattori, N; Ishida, T; Koebis, M; Kogo, Y; Nomoto, M; Suzuki, I; Tsuboi, Y, 2021) |
| "To investigate the long-term (2-year) efficacy of safinamide on PD chronic pain and to confirm the positive effects observed after 6 months of treatment." | 5.27 | Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain. ( Castellani, P; Cattaneo, C; Kulisevsky, J; Tubazio, V, 2018) |
| "Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is often limited by wearing off effect and dyskinesias." | 5.24 | Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. ( Anand, R; Fox, SH; Hauser, RA; Jankovic, J; Jost, WH; Kenney, C; Kulisevsky, J; Pahwa, R; Poewe, W; Schapira, AH, 2017) |
| "To investigate the effects of safinamide on pain management in PD patients with motor fluctuations using pooled data from studies 016 and SETTLE." | 5.24 | Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis. ( Barone, P; Bonizzoni, E; Cattaneo, C; Sardina, M, 2017) |
| "In an open pilot study, doses of safinamide (100, 150, and 200 mg once a day, higher than previously tested) were administered to 13 parkinsonian patients along with a stable dose of dopamine (DA) agonist, causing a significant progressive improvement in motor performance as evaluated by the Unified Parkinson Disease Rating Scale (UPDRS) part III over an 8-week period (4." | 5.12 | Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. ( Battaglia, G; Cattaneo, C; De Pandis, MF; Fariello, RG; Grassini, P; Stocchi, F; Vacca, L, 2006) |
| "Treatment with levodopa increases pain thresholds in patients with PD." | 5.05 | Current Status of Pain Management in Parkinson's Disease. ( Bruno, V; Farcy, N; Karnik, V; Zamorano, C, 2020) |
| "Merck Serono SA (formerly Serono), under license from Newron Pharmaceuticals SpA (following its acquisition of the rights from Pharmacia and Upjohn AB [now Pfizer Inc]), is developing the oral alpha-aminoamide derivative of milacemide, safinamide, a monoamine oxidase-B and glutamate release inhibitor, for the potential treatment of Parkinson's disease, epilepsy and restless legs syndrome." | 4.84 | Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. ( Chazot, PL, 2007) |
| "Safinamide (formerly PNU-151774E), a sodium and calcium channel modulator that also inhibits monoamine oxidase B (MAOB), is under development by Newron Pharmaceuticals for the potential treatment of epilepsy, Parkinson's disease (PD), pain and stroke [345222], [348351]." | 4.81 | Safinamide (Newron Pharmaceuticals). ( Chazot, PL, 2001) |
| "Safinamide was well-tolerated and improved sleep and daytime sleepiness in PD patients at 6 months." | 4.12 | Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study. ( Alonso Losada, MG; Cabo López, I; Cimas Hernando, MI; Cores Bartolomé, C; Gonzalez Palmás, MJ; Labandeira Guerra, C; Martínez Miró, C; Paz González, JM; Santos García, D; Yáñez Baña, R, 2022) |
| "Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS, leading to an improvement of motor complications, mood and pain." | 4.12 | Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. ( Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M, 2022) |
| "Our results suggest that safinamide may have a beneficial effect on pain, a key unmet need in fluctuating PD patients." | 4.02 | Effects of safinamide on pain in patients with fluctuating Parkinson's disease. ( Falkenburger, B; Grigoriou, S; Hausbrand, D; Leta, V; Martínez-Martín, P; Odin, P; Ray Chaudhuri, K; Reichmann, H; Rukavina, K, 2021) |
| "A enantioselective reversed-phase high performance liquid chromatographic method was developed for the enantiomeric resolution of safinamide mesilate, 2(S)-[4-(3-fluorobenzyloxy)benzylamino] propionamide methanesulfonate, a neuroprotectant with antiparkinsonian and anticonvulsant activity for the treatment of Parkinson disease." | 3.77 | A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate, a new anti-Parkinson drug. ( Du, Y; Liu, W; Meng, J; Shi, X; Xue, N; Zhang, K, 2011) |
| "Lewy bodies are found in Parkinson disease and related disorders and are extensively phosphorylated at Ser-129 (S129), but whether S129 phosphorylation mediates alpha-synuclein aggregation and neurotoxicity has been controversial." | 3.75 | Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. ( Fan, Z; Feany, MB; Hyman, BT; McFarland, NR; McLean, PJ; Schwarzschild, MA; Xu, K, 2009) |
| "Three point mutations (A30P, E46K, and A53T) as well as gene triplication genetically link the 140-residue protein alpha-synuclein (aS) to the development of Parkinson disease." | 3.73 | Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants. ( Bax, A; Ulmer, TS, 2005) |
| " Thus, alpha-synuclein immunoreactivity is found in Lewy bodies, the histopathological hallmark of sporadic Parkinson disease-affected brains." | 3.70 | Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. ( Alves da Costa, C; Ancolio, K; Checler, F; Uéda, K, 2000) |
| "Patients with Parkinson's disease (PD) experience various motor and non-motor symptoms." | 3.11 | Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study. ( Hattori, N; Ishida, T; Kamei, T; Koebis, M; Nomoto, M; Suzuki, I; Tsuboi, Y, 2022) |
| "To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions." | 3.01 | A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. ( Abbruzzese, G; Bergmans, B; Gomez-Esteban, JC; Jost, WH; Kägi, G; Kulisevsky, J; Raw, J; Stefani, A; Warnecke, T, 2021) |
| "Safinamide is a reversible and selective monoamine oxidase-B (MAO-B) and sodium channel inhibitor with demonstrated efficacy in mid-to late-stage Parkinson's disease (PD) as an adjunct to l-DOPA." | 2.94 | Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study. ( Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A, 2020) |
| "Safinamide is a unique treatment modulating both dopaminergic and glutamatergic systems." | 2.94 | Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients. ( Bonizzoni, E; Cattaneo, C; Jost, WH, 2020) |
| "Safinamide is a drug with an innovative mechanism of action, dopaminergic and non-dopaminergic, that includes the reversible inhibition of the monoamine oxidase-B (MAO-B) enzyme and the modulation of excessive glutamate release through the use- and state-dependent blockade of the sodium channels." | 2.84 | Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease. ( Bonizzoni, E; Cattaneo, C; Keywood, C; Kottakis, I; Lazzeri, G; Müller, T, 2017) |
| "Safinamide was a safe and effective first adjunct therapy in levodopa-treated patients and improved 4/5 cardinal symptoms of PD while providing benefits to mild and non-mild fluctuators and patients receiving other concomitant dopaminergic therapies." | 2.82 | Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE. ( Bonizzoni, E; Cattaneo, C; Sardina, M, 2016) |
| "Safinamide is a highly selective and reversible monoamine oxidase B inhibitor introduced in the European Union, Japan, and the United States as an adjunctive agent to levodopa in PD patients with motor fluctuation." | 2.82 | Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease. ( Fujioka, S; Kurihara, K; Mishima, T; Tsuboi, Y, 2022) |
| "Safinamide is a novel α-aminoamide with dopaminergic and non-dopaminergic properties developed as adjunctive therapy for patients with PD." | 2.80 | Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis. ( Bonizzoni, E; Cattaneo, C; Ferla, RL; Sardina, M, 2015) |
| "Safinamide is an α-aminoamide with both dopaminergic and non-dopaminergic mechanisms of action in Phase III clinical development as a once-daily add-on to dopamine agonist (DA) therapy for early Parkinson's disease (PD)." | 2.78 | Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. ( Anand, R; Bhatt, M; Borgohain, R; Giuliani, R; Lorenzana, P; Lucini, V; Onofrj, M; Schapira, AH; Stocchi, F, 2013) |
| "Safinamide is an α-aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add-on to dopamine agonist (DA) therapy in early-stage PD." | 2.77 | A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. ( Anand, R; Bhatt, M; Borgohain, R; Giuliani, R; Lucini, V; Onofrj, M; Schapira, AH; Stocchi, F, 2012) |
| "This randomized, double-blind, placebo-, comparator (selegiline 10 mg/day)-, and positive (phenelzine 30 mg/day)-controlled study investigated the pressor response to oral tyramine under fasting conditions after the administration of safinamide at therapeutic (100 mg/day) and supratherapeutic (350 mg/day) dosing regimens in healthy volunteers for the purpose of assessing the need for dietary restrictions." | 2.77 | The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. ( Astruc, B; Johne, A; Kovar, A; Krösser, S; Kupas, K; Marquet, A; Patat, A, 2012) |
| "Safinamide has been approved in over 20 countries globally for fluctuating PD as add-on therapy to levodopa regimens for the management of 'off' episodes." | 2.72 | The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature. ( Caccia, C; Jost, WH; Pagonabarraga, J; Tinazzi, M, 2021) |
| "Safinamide is an important adjunct to standard parkinsonian medication for alleviating pain in PD." | 2.58 | Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis. ( Akhter, S; Malik, SH; Qureshi, AR; Rana, AQ; Rana, R; Rizvi, SFH; Sarfraz, Z; Vannabouathong, C, 2018) |
| "The symptoms of Parkinson's disease (PD) reflect disruptions of a number of brain neurotransmitter systems of varying type and degree." | 2.55 | Clinical Pharmacokinetics and Pharmacodynamics of Safinamide. ( Foley, P; Müller, T, 2017) |
| "The major unmet needs in the medical treatment of Parkinson disease (PD) are reduction of motor side effects from dopaminergic drugs, management of non-motor symptoms and disease modification." | 2.55 | Safinamide for the treatment of Parkinson's disease. ( deSouza, RM; Schapira, A, 2017) |
| "Safinamide was well tolerated and safe when administered in dose of 50 or 100 mg daily in pivotal trials." | 2.55 | Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease. ( Müller, T, 2017) |
| "Safinamide (SAF) is a new drug developed for the treatment of Parkinson's disease (PD)." | 2.53 | Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide. ( Stocchi, F; Torti, M, 2016) |
| "Safinamide was recently licensed by EMA for the treatment of PD as add-on therapy to a stable dose of levodopa alone or in combination with other PD medicinal products in mid-to advanced-stage fluctuating patients." | 2.53 | The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. ( Perez-Lloret, S; Rascol, O, 2016) |
| "Safinamide is a novel instrument for the drug therapy of Parkinson's disease with better safety and tolerability particularly concerning diarrhea than inhibitors of catechol-O-methyltransferase, like entacapone, according to an indirect comparison within a meta-analysis with entacapone." | 2.52 | Safinamide for symptoms of Parkinson's disease. ( Müller, T, 2015) |
| "Safinamide (Xadago(®)) is an oral α-aminoamide derivative developed by Newron for the treatment of Parkinson's disease (PD)." | 2.52 | Safinamide: first global approval. ( Deeks, ED, 2015) |
| "Safinamide (Xadago™) is an oral α-aminoamide derivative marketed for the treatment of Parkinson's disease (PD)." | 2.52 | Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. ( Abreu, D; Fabbri, M; Ferreira, JJ; Rosa, MM, 2015) |
| "Safinamide is an α-aminoamide derivative with a combined, dopaminergic and non-dopaminergic mode of action." | 2.50 | Safinamide for the treatment of Parkinson's disease. ( Dézsi, L; Vécsei, L, 2014) |
| "Safinamide (NW-1015) is a novel drug with multiple actions." | 2.50 | Safinamide for the treatment of Parkinson's disease. ( Borgohain, R; Jabeen, SA; Kandadai, RM; Kanikannan, MA, 2014) |
| "Safinamide has a unique pharmacological profile, which combines modulation of dopamine metabolism by reversible, highly specific monoamine oxidase-B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and of glutamate release induced by abnormal neuronal activity." | 2.49 | Current status of safinamide for the drug portfolio of Parkinson's disease therapy. ( Müller, T, 2013) |
| "Current therapy for Parkinson's disease (PD) is primarily directed at reversing the motor symptoms that are the consequence of dopamine deficiency and includes levodopa, dopamine agonists and monoamine oxidase (MAO) B inhibitors." | 2.46 | Safinamide in the treatment of Parkinson's disease. ( Schapira, AH, 2010) |
| "Safinamide is an investigational drug for PD currently in development as add-on therapy to both dopamine agonists and levodopa." | 2.44 | An expert opinion on safinamide in Parkinson's disease. ( Bonanni, L; Onofrj, M; Thomas, A, 2008) |
| " The oral disintegrating tablet formulation of selegiline allows pregastric absorption, minimizing first-pass metabolism, thereby increasing selegiline bioavailability and reducing the concentration of amphetamine metabolites." | 2.44 | Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. ( Chen, JJ; Fernandez, HH, 2007) |
| "Safinamide was originated by Farmitalia-CarloErba in Italy." | 2.42 | Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E. ( , 2004) |
| "Neuropathic pain is highly prevalent in PD and negatively affects the quality of life of patients with PD." | 1.91 | Analgesic effect of safinamide mesylate in a rat model of neuropathic pain. ( Ishida, T; Kobayashi, Y; Koebis, M; Kogo, Y; Maeda, T, 2023) |
| "Safinamide is a monoamine oxidase B (MAOB) inhibitor that facilitates CDS." | 1.91 | The effects of safinamide on dysphagia in Parkinson's disease. ( Hirano, M; Isono, C; Nagai, Y; Samukawa, M, 2023) |
| "Safinamide is a new monoamine oxidase B inhibitor, also exerting a non-dopaminergic effect, recently approved as add-on therapy in fluctuating PD patients." | 1.72 | Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study. ( De Mase, A; De Micco, R; Giordano, A; Satolli, S; Siciliano, M; Tedeschi, G; Tessitore, A, 2022) |
| "Treatment with safinamide was associated with significant increases of the total FAB score, SWCT-interference time score and UPDRS-III score." | 1.62 | Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. ( Assogna, F; Caltagirone, C; Pontieri, FE; Rinaldi, D; Salvetti, M; Savini, C; Sforza, M; Spalletta, G, 2021) |
| "The results of the present study confirm that the overnight switch from rasagiline to safinamide is safe and well tolerated by patients." | 1.62 | Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study. ( Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M, 2021) |
| "Safinamide (SF) is a third-generation monoamine-oxidase-B inhibitor that proved efficacy as add-on to levodopa in fluctuating Parkinson's disease (PD) patients." | 1.62 | The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study. ( Alborghetti, M; Bianchini, E; Galli, S; Giovannelli, M; Pontieri, FE; Rinaldi, D; Salvetti, M; Sforza, M, 2021) |
| "Mood disorders are frequent in Parkinson's disease (PD) and a favorable effect of safinamide on mood has been observed." | 1.62 | Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR. ( Alonso Losada, MG; Cabo López, I; Cimas Hernando, MI; Gonzalez Palmás, MJ; Labandeira, CM; Martínez Miró, C; Paz González, JM; Santos García, D; Yáñez Baña, R, 2021) |
| " Harms are typically assessed through the collection of adverse events (AEs)." | 1.56 | Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials. ( Cornelius, V; Cro, S; Phillips, R, 2020) |
| " We found that early accumulation of KARs occurs in the DA neurons of the parkinQ311X mouse, and that chronic administration of the KAR antagonist UBP310 prevents DA neuron loss." | 1.56 | Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity. ( Albanese, F; Bagnati, R; Cattaneo, S; Ciammola, A; Consalez, GG; Croci, L; Davoli, E; Di Fonzo, A; Mercatelli, D; Morari, M; Novello, S; Passafaro, M; Passoni, A; Regoni, M; Sassone, J; Serratto, GM; Taverna, S; Valtorta, F; Zanetti, L, 2020) |
| " Adverse events (AEs) occurred in 78." | 1.56 | Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study. ( Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A, 2020) |
| "Pain is a common and disabling non-motor symptom (NMS) of Parkinson's disease (PD), which occurs through the course of the disease, often unrecognized and undertreated." | 1.56 | Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study. ( Bovi, T; Di Vico, IA; Geroin, C; Segatti, A; Squintani, G; Tinazzi, M, 2020) |
| "Safinamide use was categorized as never used, ongoing, and withdrawn." | 1.56 | Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study. ( Bentivoglio, AR; Di Stasio, E; Fusco, D; Laudisio, A; Lo Monaco, MR; Onder, G; Petracca, M; Ricciardi, D; Vetrano, DL; Zuccalà, G, 2020) |
| "A total of 724 patients with Parkinson's disease (PD) have been prospectively included in our database since the year 2000, representing a total of 5124 visits." | 1.51 | Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease. ( Avila, A; Balagué-Marmaña, M; Caballol, N; Cardona, X; Gómez-Ruiz, I; Martín-Baranera, M; Planas-Ballvé, A, 2019) |
| " In total, 300 adverse events were classified as related to safinamide in 132 patients (44." | 1.48 | [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study]. ( Bosse, D; Delf, M; Jost, WH; Kupsch, A; Mengs, J, 2018) |
| "Safinamide (Xadago) is a novel dual-mechanism drug that has been approved in the European Union and United States as add-on treatment to levodopa in Parkinson's disease therapy." | 1.48 | Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia. ( Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S, 2018) |
| "Evaluations were based on the Unified Parkinson's Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD)." | 1.48 | Real life evaluation of safinamide effectiveness in Parkinson's disease. ( Borellini, L; Comi, C; Di Fonzo, A; Lacerenza, M; Lazzeri, G; Mancini, F; Silani, V, 2018) |
| "The association between idiopathic Parkinson's disease (PD) and the ATP13A2 (PARK9) Ala746Thr variant, associated with Kufor-Rakeb syndrome, is controversial." | 1.39 | The role of the Ala746Thr variant in the ATP13A2 gene among Chinese patients with Parkinson's disease. ( Baum, L; Chan, AY; Hui, KF; Kuo, SH; Kwan, JY; Lau, CY; Mizuno, Y; Mok, VC; Ng, PW; Tang, NL, 2013) |
| "Classical pathological signs of Parkinson's disease (PD) include loss of dopaminergic neurons in substantia nigra (SN) and noradrenergic neurons in locus coeruleus (LC), and deposition of Lewy bodies rich in the presynaptic protein alpha-synuclein (ASYN)." | 1.36 | Selective noradrenergic vulnerability in α-synuclein transgenic mice. ( Sotiriou, E; Stefanis, L; Vassilatis, DK; Vila, M, 2010) |
| "The Unified Parkinson's disease rating scale (UPDRS) was also completed." | 1.32 | Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. ( Athanassiadou, A; Ellul, J; Papadimitriou, A; Papapetropoulos, S; Papapetropoulos, T; Paschalis, C, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.77) | 18.7374 |
| 1990's | 2 (1.54) | 18.2507 |
| 2000's | 27 (20.77) | 29.6817 |
| 2010's | 59 (45.38) | 24.3611 |
| 2020's | 41 (31.54) | 2.80 |
| Authors | Studies |
|---|---|
| Grigoriou, S | 1 |
| Martínez-Martín, P | 1 |
| Ray Chaudhuri, K | 1 |
| Rukavina, K | 1 |
| Leta, V | 1 |
| Hausbrand, D | 1 |
| Falkenburger, B | 1 |
| Odin, P | 1 |
| Reichmann, H | 1 |
| Tsuboi, Y | 6 |
| Koebis, M | 3 |
| Kogo, Y | 2 |
| Ishida, T | 4 |
| Suzuki, I | 3 |
| Nomoto, M | 5 |
| Hattori, N | 5 |
| Labandeira, CM | 1 |
| Alonso Losada, MG | 2 |
| Yáñez Baña, R | 2 |
| Cimas Hernando, MI | 2 |
| Cabo López, I | 2 |
| Paz González, JM | 2 |
| Gonzalez Palmás, MJ | 2 |
| Martínez Miró, C | 2 |
| Santos García, D | 2 |
| Labandeira Guerra, C | 1 |
| Cores Bartolomé, C | 1 |
| Kurihara, K | 1 |
| Mishima, T | 1 |
| Fujioka, S | 1 |
| Meade, RM | 1 |
| Watt, KJC | 1 |
| Williams, RJ | 1 |
| Mason, JM | 1 |
| Larson, D | 1 |
| Simuni, T | 1 |
| Rizzone, MG | 1 |
| Mancini, F | 2 |
| Artusi, CA | 1 |
| Balestrino, R | 1 |
| Bonvegna, S | 1 |
| Fabbri, M | 2 |
| Imbalzano, G | 1 |
| Montanaro, E | 1 |
| Romagnolo, A | 1 |
| Zibetti, M | 1 |
| Lopiano, L | 2 |
| Kamei, T | 2 |
| Rodríguez-Jorge, F | 1 |
| Beltrán-Corbellini, Á | 1 |
| Chico-García, JL | 1 |
| Parra-Díaz, P | 1 |
| Baena-Álvarez, B | 1 |
| Pagonabarraga, J | 3 |
| Pérez-Torre, P | 1 |
| Pareés, I | 1 |
| López-Sendón, JL | 1 |
| Martínez-Castrillo, JC | 1 |
| Alonso-Cánovas, A | 1 |
| Talavera Andújar, B | 1 |
| Aurich, D | 1 |
| Aho, VTE | 1 |
| Singh, RR | 1 |
| Cheng, T | 1 |
| Zaslavsky, L | 1 |
| Bolton, EE | 1 |
| Mollenhauer, B | 1 |
| Wilmes, P | 1 |
| Schymanski, EL | 1 |
| Yan, Z | 1 |
| Li, R | 1 |
| Shi, W | 1 |
| Yao, L | 1 |
| De Masi, C | 1 |
| Liguori, C | 3 |
| Spanetta, M | 1 |
| Fernandes, M | 1 |
| Cerroni, R | 1 |
| Garasto, E | 1 |
| Pierantozzi, M | 3 |
| Mercuri, NB | 3 |
| Stefani, A | 4 |
| El-Sayed, HM | 1 |
| El-Abassy, OM | 1 |
| Abdellatef, HE | 1 |
| Hendawy, HAM | 1 |
| Ibrahim, H | 1 |
| Hirano, M | 1 |
| Samukawa, M | 1 |
| Isono, C | 1 |
| Nagai, Y | 1 |
| Kobayashi, Y | 1 |
| Maeda, T | 1 |
| Silva da Fonsêca, V | 1 |
| Goncalves, VC | 1 |
| Augusto Izidoro, M | 1 |
| Guimarães de Almeida, AC | 1 |
| Luiz Affonso Fonseca, F | 1 |
| Alexandre Scorza, F | 1 |
| Finsterer, J | 1 |
| Scorza, CA | 1 |
| Cattaneo, C | 8 |
| Jost, WH | 5 |
| Bonizzoni, E | 5 |
| Kilpeläinen, T | 1 |
| Julku, UH | 1 |
| Svarcbahs, R | 1 |
| Myöhänen, TT | 1 |
| Karnik, V | 1 |
| Farcy, N | 1 |
| Zamorano, C | 1 |
| Bruno, V | 1 |
| Lo Monaco, MR | 1 |
| Petracca, M | 1 |
| Vetrano, DL | 1 |
| Di Stasio, E | 1 |
| Fusco, D | 1 |
| Ricciardi, D | 1 |
| Laudisio, A | 1 |
| Zuccalà, G | 1 |
| Onder, G | 1 |
| Bentivoglio, AR | 1 |
| Parambi, DGT | 1 |
| Abdelalem Aziz Ahmed, M | 1 |
| Yamamoto, A | 2 |
| Sasagawa, Y | 2 |
| Geroin, C | 1 |
| Di Vico, IA | 1 |
| Squintani, G | 1 |
| Segatti, A | 1 |
| Bovi, T | 1 |
| Tinazzi, M | 2 |
| Müller, T | 7 |
| Rinaldi, D | 3 |
| Bianchini, E | 2 |
| Sforza, M | 3 |
| Alborghetti, M | 3 |
| Galli, S | 1 |
| Salvetti, M | 2 |
| Giovannelli, M | 1 |
| Pontieri, FE | 3 |
| Gonzalez-Latapi, P | 1 |
| Bhowmick, SS | 1 |
| Saranza, G | 1 |
| Fox, SH | 2 |
| Stocchi, F | 9 |
| Vacca, L | 2 |
| Grassini, P | 2 |
| Tomino, C | 1 |
| Caminiti, G | 1 |
| Casali, M | 1 |
| D'Antoni, V | 1 |
| Volterrani, M | 1 |
| Torti, M | 2 |
| Assogna, F | 1 |
| Savini, C | 1 |
| Caltagirone, C | 1 |
| Spalletta, G | 1 |
| Abbruzzese, G | 2 |
| Kulisevsky, J | 5 |
| Bergmans, B | 1 |
| Gomez-Esteban, JC | 1 |
| Kägi, G | 1 |
| Raw, J | 1 |
| Warnecke, T | 1 |
| Regoni, M | 1 |
| Cattaneo, S | 1 |
| Mercatelli, D | 1 |
| Novello, S | 2 |
| Passoni, A | 1 |
| Bagnati, R | 1 |
| Davoli, E | 1 |
| Croci, L | 1 |
| Consalez, GG | 1 |
| Albanese, F | 1 |
| Zanetti, L | 1 |
| Passafaro, M | 1 |
| Serratto, GM | 1 |
| Di Fonzo, A | 2 |
| Valtorta, F | 1 |
| Ciammola, A | 1 |
| Taverna, S | 1 |
| Morari, M | 2 |
| Sassone, J | 1 |
| Cornelius, V | 1 |
| Cro, S | 1 |
| Phillips, R | 1 |
| Wasan, H | 1 |
| Singh, D | 1 |
| Kh, R | 1 |
| Giossi, R | 1 |
| Carrara, F | 1 |
| Mazzari, M | 1 |
| Lo Re, F | 1 |
| Senatore, M | 1 |
| Schicchi, A | 1 |
| Corrù, F | 1 |
| Fittipaldo, VA | 1 |
| Pani, A | 1 |
| Tramacere, I | 1 |
| Elia, AE | 1 |
| Scaglione, F | 1 |
| De Micco, R | 1 |
| Satolli, S | 1 |
| Siciliano, M | 1 |
| De Mase, A | 1 |
| Giordano, A | 1 |
| Tedeschi, G | 1 |
| Tessitore, A | 1 |
| Barone, P | 2 |
| De Carolis, L | 1 |
| Della Gatta, F | 1 |
| Caccia, C | 2 |
| Plastino, M | 1 |
| Gorgone, G | 1 |
| Fava, A | 1 |
| Ettore, M | 1 |
| Iannacchero, R | 1 |
| Scarfone, R | 1 |
| Vaccaro, A | 1 |
| De Bartolo, M | 1 |
| Bosco, D | 1 |
| Elkamhawy, A | 1 |
| Paik, S | 1 |
| Park, JH | 1 |
| Kim, HJ | 1 |
| Hassan, AHE | 1 |
| Lee, K | 1 |
| Park, KD | 1 |
| Roh, EJ | 1 |
| deSouza, RM | 1 |
| Schapira, A | 1 |
| Aschenbrenner, DS | 1 |
| Lazzeri, G | 2 |
| Kottakis, I | 1 |
| Keywood, C | 2 |
| Jiménez-Jiménez, FJ | 1 |
| Alonso-Navarro, H | 1 |
| Valle-Arcos, D | 1 |
| Teixeira, FG | 1 |
| Gago, MF | 1 |
| Marques, P | 1 |
| Moreira, PS | 1 |
| Magalhães, R | 1 |
| Sousa, N | 1 |
| Salgado, AJ | 1 |
| Borellini, L | 1 |
| Silani, V | 1 |
| Lacerenza, M | 1 |
| Comi, C | 1 |
| Nagesh Babu, G | 1 |
| Gupta, M | 1 |
| Paliwal, VK | 1 |
| Singh, S | 1 |
| Chatterji, T | 1 |
| Roy, R | 1 |
| Kuang, S | 1 |
| Yang, L | 1 |
| Rao, Z | 1 |
| Zhong, Z | 1 |
| Li, J | 1 |
| Zhong, H | 1 |
| Dai, L | 1 |
| Tang, X | 1 |
| Tubazio, V | 1 |
| Castellani, P | 1 |
| Henrich, MT | 1 |
| Geibl, FF | 1 |
| Lee, B | 1 |
| Chiu, WH | 1 |
| Koprich, JB | 1 |
| Brotchie, JM | 1 |
| Timmermann, L | 1 |
| Decher, N | 1 |
| Matschke, LA | 1 |
| Oertel, WH | 1 |
| Ruffini, R | 1 |
| Kupsch, A | 1 |
| Mengs, J | 1 |
| Delf, M | 1 |
| Bosse, D | 1 |
| Qureshi, AR | 1 |
| Rana, AQ | 1 |
| Malik, SH | 1 |
| Rizvi, SFH | 1 |
| Akhter, S | 1 |
| Vannabouathong, C | 1 |
| Sarfraz, Z | 1 |
| Rana, R | 1 |
| Nicoletti, F | 1 |
| Koros, C | 1 |
| Simitsi, A | 1 |
| Prentakis, A | 1 |
| Beratis, I | 1 |
| Papadimitriou, D | 1 |
| Kontaxopoulou, D | 1 |
| Fragkiadaki, S | 1 |
| Papagiannakis, N | 1 |
| Seibyl, J | 1 |
| Marek, K | 1 |
| Papageorgiou, SG | 1 |
| Trapali, XG | 1 |
| Stamelou, M | 1 |
| Stefanis, L | 2 |
| Gardoni, F | 1 |
| Brugnoli, A | 1 |
| Pisanò, CA | 1 |
| Mellone, M | 1 |
| Melloni, E | 1 |
| Padoani, G | 1 |
| Sosti, V | 1 |
| Vailati, S | 1 |
| Bianchi, MLE | 1 |
| Riboldazzi, G | 1 |
| Mauri, M | 1 |
| Versino, M | 1 |
| Avila, A | 1 |
| Caballol, N | 1 |
| Martín-Baranera, M | 1 |
| Gómez-Ruiz, I | 1 |
| Balagué-Marmaña, M | 1 |
| Planas-Ballvé, A | 1 |
| Cardona, X | 1 |
| Chan, AY | 1 |
| Baum, L | 1 |
| Tang, NL | 1 |
| Lau, CY | 1 |
| Ng, PW | 1 |
| Hui, KF | 1 |
| Mizuno, Y | 1 |
| Kwan, JY | 1 |
| Mok, VC | 1 |
| Kuo, SH | 1 |
| Gopalai, AA | 1 |
| Lim, SY | 1 |
| Aziz, ZA | 1 |
| Lim, SK | 1 |
| Tan, LP | 1 |
| Chong, YB | 1 |
| Tan, CT | 1 |
| Puvanarajah, S | 1 |
| Viswanathan, S | 1 |
| Kuppusamy, R | 1 |
| Tan, AH | 1 |
| Lim, TT | 1 |
| Eow, GB | 1 |
| Norlinah, MI | 1 |
| Li, HH | 1 |
| Zhao, Y | 1 |
| Ahmad-Annuar, A | 1 |
| Kolisek, M | 1 |
| Sponder, G | 1 |
| Mastrototaro, L | 1 |
| Smorodchenko, A | 1 |
| Launay, P | 1 |
| Vormann, J | 1 |
| Schweigel-Röntgen, M | 1 |
| Leuratti, C | 1 |
| Sardina, M | 4 |
| Ventura, P | 1 |
| Assandri, A | 1 |
| Müller, M | 1 |
| Brunner, M | 1 |
| Borgohain, R | 5 |
| Szasz, J | 2 |
| Stanzione, P | 2 |
| Meshram, C | 2 |
| Bhatt, M | 3 |
| Chirilineau, D | 2 |
| Lucini, V | 4 |
| Giuliani, R | 4 |
| Forrest, E | 2 |
| Rice, P | 2 |
| Anand, R | 5 |
| Muda, K | 1 |
| Bertinetti, D | 1 |
| Gesellchen, F | 1 |
| Hermann, JS | 1 |
| von Zweydorf, F | 1 |
| Geerlof, A | 1 |
| Jacob, A | 1 |
| Ueffing, M | 1 |
| Gloeckner, CJ | 1 |
| Herberg, FW | 1 |
| Dézsi, L | 1 |
| Vécsei, L | 1 |
| Bhatt, MH | 1 |
| Kandadai, RM | 1 |
| Jabeen, SA | 1 |
| Kanikannan, MA | 1 |
| Kakkar, AK | 1 |
| Dahiya, N | 1 |
| Deeks, ED | 1 |
| Ferla, RL | 1 |
| Rosa, MM | 1 |
| Abreu, D | 1 |
| Ferreira, JJ | 1 |
| Yamasaki, T | 1 |
| Fujinaga, M | 1 |
| Kawamura, K | 1 |
| Furutsuka, K | 1 |
| Nengaki, N | 1 |
| Shimoda, Y | 1 |
| Shiomi, S | 1 |
| Takei, M | 1 |
| Hashimoto, H | 1 |
| Yui, J | 1 |
| Wakizaka, H | 1 |
| Hatori, A | 1 |
| Xie, L | 1 |
| Kumata, K | 1 |
| Zhang, MR | 1 |
| Perez-Lloret, S | 1 |
| Rascol, O | 1 |
| Foley, P | 1 |
| Schapira, AH | 4 |
| Hauser, RA | 1 |
| Jankovic, J | 1 |
| Kenney, C | 1 |
| Pahwa, R | 1 |
| Poewe, W | 1 |
| Blair, HA | 1 |
| Dhillon, S | 1 |
| Onofrj, M | 4 |
| Bonanni, L | 1 |
| Thomas, A | 2 |
| Ulrih, NP | 1 |
| Barry, CH | 1 |
| Fink, AL | 1 |
| Lin, CH | 1 |
| Tan, EK | 1 |
| Chen, ML | 1 |
| Tan, LC | 1 |
| Lim, HQ | 1 |
| Chen, GS | 1 |
| Wu, RM | 1 |
| Sotiriou, E | 1 |
| Vassilatis, DK | 1 |
| Vila, M | 1 |
| McFarland, NR | 1 |
| Fan, Z | 1 |
| Xu, K | 1 |
| Schwarzschild, MA | 1 |
| Feany, MB | 1 |
| Hyman, BT | 1 |
| McLean, PJ | 1 |
| Mao, XY | 1 |
| Burgunder, JM | 2 |
| Zhang, ZJ | 2 |
| Chang, XL | 1 |
| Peng, R | 1 |
| Yang, Y | 1 |
| Wang, YC | 1 |
| Li, T | 1 |
| Bodner, CR | 1 |
| Maltsev, AS | 1 |
| Dobson, CM | 1 |
| Bax, A | 2 |
| Yamamoto-Watanabe, Y | 1 |
| Watanabe, M | 1 |
| Jackson, M | 1 |
| Akimoto, H | 1 |
| Sugimoto, K | 1 |
| Yasujima, M | 1 |
| Wakasaya, Y | 1 |
| Matsubara, E | 1 |
| Kawarabayashi, T | 1 |
| Harigaya, Y | 1 |
| Lyndon, AR | 1 |
| Shoji, M | 1 |
| Zhang, K | 1 |
| Xue, N | 1 |
| Shi, X | 1 |
| Liu, W | 1 |
| Meng, J | 1 |
| Du, Y | 1 |
| Quadri, M | 1 |
| Cossu, G | 1 |
| Saddi, V | 1 |
| Simons, EJ | 1 |
| Murgia, D | 1 |
| Melis, M | 1 |
| Ticca, A | 1 |
| Oostra, BA | 1 |
| Bonifati, V | 1 |
| Marquet, A | 1 |
| Kupas, K | 1 |
| Johne, A | 1 |
| Astruc, B | 1 |
| Patat, A | 1 |
| Krösser, S | 1 |
| Kovar, A | 1 |
| Lorenzana, P | 1 |
| Wang, V | 1 |
| Chuang, TC | 1 |
| Kao, MC | 1 |
| Shan, DE | 1 |
| Soong, BW | 1 |
| Shieh, TM | 1 |
| García-Lozano, JR | 1 |
| Mir, P | 1 |
| Alberca, R | 1 |
| Aguilera, I | 1 |
| Gil Néciga, E | 1 |
| Fernández-López, O | 1 |
| Cayuela, A | 1 |
| Núñez-Roldan, A | 1 |
| Papapetropoulos, S | 1 |
| Ellul, J | 1 |
| Paschalis, C | 1 |
| Athanassiadou, A | 2 |
| Papadimitriou, A | 1 |
| Papapetropoulos, T | 1 |
| Bussell, R | 1 |
| Eliezer, D | 1 |
| Arnold, G | 1 |
| Kwiecinski, H | 1 |
| Szczudlik, A | 1 |
| Bonuccelli, U | 1 |
| Van Dijk, A | 1 |
| Sala, P | 1 |
| Fariello, RG | 3 |
| Lo Bianco, C | 1 |
| Schneider, BL | 1 |
| Bauer, M | 1 |
| Sajadi, A | 1 |
| Brice, A | 1 |
| Iwatsubo, T | 1 |
| Aebischer, P | 1 |
| Cabin, DE | 1 |
| Gispert-Sanchez, S | 1 |
| Murphy, D | 1 |
| Auburger, G | 1 |
| Myers, RR | 1 |
| Nussbaum, RL | 1 |
| Frasier, M | 2 |
| Walzer, M | 1 |
| McCarthy, L | 1 |
| Magnuson, D | 1 |
| Lee, JM | 1 |
| Haas, C | 1 |
| Kahle, P | 1 |
| Wolozin, B | 2 |
| Poon, HF | 1 |
| Shreve, N | 1 |
| Calabrese, V | 1 |
| Butterfield, DA | 1 |
| Ulmer, TS | 1 |
| Martin, LJ | 1 |
| Pan, Y | 1 |
| Price, AC | 1 |
| Sterling, W | 1 |
| Copeland, NG | 2 |
| Jenkins, NA | 2 |
| Price, DL | 2 |
| Lee, MK | 2 |
| De Pandis, MF | 1 |
| Battaglia, G | 1 |
| Horvath, R | 1 |
| Kley, RA | 1 |
| Lochmüller, H | 1 |
| Vorgerd, M | 1 |
| Ki, CS | 1 |
| Stavrou, EF | 1 |
| Davanos, N | 1 |
| Lee, WY | 1 |
| Chung, EJ | 1 |
| Kim, JY | 1 |
| Herrera, FE | 1 |
| Zucchelli, S | 1 |
| Jezierska, A | 1 |
| Lavina, ZS | 1 |
| Gustincich, S | 1 |
| Carloni, P | 1 |
| Chazot, PL | 2 |
| Fernandez, HH | 1 |
| Chen, JJ | 1 |
| Yamaguchi, T | 1 |
| Nagatsu, T | 1 |
| Sugimoto, T | 1 |
| Matsuura, S | 1 |
| Kondo, T | 1 |
| Iizuka, R | 1 |
| Narabayashi, H | 1 |
| Krüger, R | 1 |
| Kuhn, W | 1 |
| Woitalla, D | 1 |
| Graeber, M | 1 |
| Kösel, S | 1 |
| Przuntek, H | 1 |
| Epplen, JT | 1 |
| Schöls, L | 1 |
| Riess, O | 1 |
| Conway, KA | 3 |
| Harper, JD | 2 |
| Lansbury, PT | 3 |
| Ancolio, K | 1 |
| Alves da Costa, C | 1 |
| Uéda, K | 1 |
| Checler, F | 1 |
| Rochet, JC | 1 |
| Stirling, W | 1 |
| Xu, Y | 1 |
| Xu, X | 1 |
| Qui, D | 1 |
| Mandir, AS | 1 |
| Dawson, TM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Blood Dopamine Levels in Idiopathic Parkinson's Patients Receiving Levodopa Carbidopa Entacapone or Levodopa Benserazide[NCT06115538] | Phase 4 | 96 participants (Anticipated) | Interventional | 2023-10-01 | Enrolling by invitation | ||
| A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated Wit[NCT00627640] | Phase 3 | 549 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study[NCT03843944] | Phase 4 | 20 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| -Clinical Efficacy of Pharmacological Treatments Targeting Energy Metabolism, Evaluated by Gait Analysis, on Motor Function in Parkinson's Disease Patients[NCT05855577] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
35 reviews available for alanine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; P | 2022 |
New dopaminergic therapies for PD motor complications.
Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progr | 2022 |
Current Status of Pain Management in Parkinson's Disease.
Topics: Acetylcholine Release Inhibitors; Alanine; Analgesics; Antiparkinson Agents; Apomorphine; Benzylamin | 2020 |
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therap | 2020 |
A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease; Quality of Life; R | 2019 |
Safinamide in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Alanine; Antiparkinson Agents; Benzylamines; Catechol O-Methyltransferase Inhibit | 2020 |
Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Development; Drug Repositioning; Humans; | 2020 |
Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies.
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Humans; Monoamine Oxidase; Ne | 2021 |
Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; | 2021 |
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; M | 2021 |
The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Male; Middle Aged; Neurons; Parki | 2021 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Humans; Levodopa; Parkinson | 2017 |
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, | 2017 |
Safinamide: a new hope for Parkinson's disease?
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Neuroprotective Agents; Park | 2018 |
▼ Safinamide for Parkinson's disease.
Topics: Alanine; Benzylamines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoam | 2018 |
Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Topics: Alanine; Analgesics; Benzylamines; Electric Stimulation Therapy; Humans; Pain; Pain Management; Park | 2018 |
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoam | 2019 |
Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Humans; Parkinson Disease | 2013 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Clinical Trials as Topic; Humans; Monoamine Oxidase; Monoamine Oxida | 2014 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Disease Progression; Dopamine; Dopamine Agents | 2014 |
Management of Parkinson׳s disease: Current and future pharmacotherapy.
Topics: Adenosine A2 Receptor Antagonists; Alanine; Animals; Benzylamines; Drug Therapy; Humans; Levodopa; P | 2015 |
Safinamide: first global approval.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Cognition Disorders; Drug Approval; Dyskinesia | 2015 |
Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Disease Progression; | 2015 |
Safinamide for symptoms of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkin | 2015 |
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease | 2016 |
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
Topics: Adult; Aged; Alanine; Benzylamines; Double-Blind Method; Humans; Middle Aged; Monoamine Oxidase Inhi | 2016 |
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Monoamine Oxidase; Monoamine Oxidase I | 2017 |
Safinamide: A Review in Parkinson's Disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2017 |
An expert opinion on safinamide in Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Drug Design; Drug Tolerance; Humans; Neuroprotective Agents; Parkins | 2008 |
Safinamide in the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Disease Progression; | 2010 |
Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Clinical Trials, Phase I as T | 2004 |
Safinamide.
Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Brain; Clinical Trials as Topic; Epilepsy; Humans; | 2007 |
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Topics: Alanine; Animals; Benzylamines; Clinical Trials as Topic; Epilepsy; Humans; Molecular Structure; Mon | 2007 |
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine | 2007 |
Safinamide (Newron Pharmaceuticals).
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Con | 2001 |
21 trials available for alanine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Pain; Parkinson Disease | 2021 |
Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease | 2022 |
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson's disease: post-hoc analysis of a Japanese phase III study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dyskinesias; Humans; Japan; Levodopa; Parkinson Disease | 2022 |
Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; | 2020 |
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; F | 2020 |
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
Topics: Aged; Aged, 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse R | 2021 |
Effects of safinamide on REM sleep behavior disorder in Parkinson disease: A randomized, longitudinal, cross-over pilot study.
Topics: Alanine; Benzylamines; Cross-Over Studies; Humans; Parkinson Disease; Pilot Projects; Polysomnograph | 2021 |
Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.
Topics: Alanine; Benzylamines; Double-Blind Method; Enzyme Inhibitors; Female; Humans; International Coopera | 2017 |
Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Chronic Pain; Double-Blind Method; Humans; Pain Managem | 2018 |
Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers.
Topics: Adult; Alanine; Benzylamines; Feces; Healthy Volunteers; Humans; Male; Parkinson Disease; Young Adul | 2013 |
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relatio | 2014 |
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Me | 2014 |
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2015 |
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; F | 2016 |
Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis.
Topics: Adult; Aged; Alanine; Benzylamines; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome | 2017 |
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relations | 2017 |
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relations | 2017 |
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relations | 2017 |
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relations | 2017 |
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Analysis of Variance; Antiparkinson Agents; Benzylamines; D | 2012 |
The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial.
Topics: Administration, Oral; Adult; Aged; Alanine; Benzylamines; Blood Pressure; Dose-Response Relationship | 2012 |
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Doub | 2013 |
Improvement of motor function in early Parkinson disease by safinamide.
Topics: Adult; Aged; Alanine; Antiparkinson Agents; Benzylamines; Calcium Channel Blockers; Dopamine Agonist | 2004 |
Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
Topics: Adult; Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Drug Therapy, Combina | 2006 |
74 other studies available for alanine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Pain; Parkinson Disease; Pilot Projects; Qualit | 2021 |
Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR.
Topics: Aged; Alanine; Benzylamines; Female; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studi | 2021 |
Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study.
Topics: Aged; Alanine; Benzylamines; Disorders of Excessive Somnolence; Female; Humans; Male; Middle Aged; P | 2022 |
A Downsized and Optimised Intracellular Library-Derived Peptide Prevents Alpha-Synuclein Primary Nucleation and Toxicity Without Impacting Upon Lipid Binding.
Topics: Alanine; alpha-Synuclein; Antiparkinson Agents; Cryoelectron Microscopy; Cytoplasmic Vesicles; Dopam | 2021 |
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
Topics: Alanine; Benzylamines; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Pain; Parkinson Diseas | 2022 |
Efficacy and safety of high doses of safinamide in advanced Parkinson disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease | 2022 |
Studying the Parkinson's disease metabolome and exposome in biological samples through different analytical and cheminformatics approaches: a pilot study.
Topics: Aged; Alanine; Betaine; Cheminformatics; Exposome; Humans; Metabolome; Metabolomics; Neurodegenerati | 2022 |
Role of the gut-microbiota-metabolite axis in the rotenone model of early-stage Parkinson's Disease.
Topics: Alanine; Animals; Asparagine; Gastrointestinal Microbiome; Glutamine; Hydroxyproline; Methionine; Mi | 2022 |
Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study.
Topics: Alanine; Benzylamines; Fatigue; Female; Humans; Male; Pain; Parkinson Disease; Quality of Life | 2022 |
Green Spectrophotometric Platforms for Resolving Overlapped Spectral Signals of Recently Approved Antiparkinsonian Drug (Safinamide) in the Presence of Its Synthetic Precursor (4-Hydroxybenzaldehyde): Applying Ecological Appraisal and Comparative Statisti
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Parkinson Disease | 2022 |
The effects of safinamide on dysphagia in Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Deglutition Disorders; Humans; Levodopa; Monoamine Oxid | 2023 |
Analgesic effect of safinamide mesylate in a rat model of neuropathic pain.
Topics: Alanine; Analgesics; Animals; Antiparkinson Agents; Benzylamines; Male; Mesylates; Monoamine Oxidase | 2023 |
Parkinson's Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model.
Topics: Alanine; Animals; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Quality of Life; Rats | 2023 |
Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease.
Topics: Aging; Alanine; alpha-Synuclein; Amino Acid Substitution; Animals; Behavior, Animal; Disease Models, | 2019 |
Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Combined Modality Therapy; Hospitalization; Human | 2020 |
Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Pain; Parkinson Disease; Quality of Life | 2020 |
Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease | 2020 |
The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Humans; Parkinson Disease; Retrospective Studies | 2021 |
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Indans; Levodopa; Mo | 2021 |
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Executive Function; Humans; Levodopa; Parkinson Disease | 2021 |
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity.
Topics: Alanine; Animals; Disease Models, Animal; Dopaminergic Neurons; Down-Regulation; Female; GluK2 Kaina | 2020 |
Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials.
Topics: Adenosine Monophosphate; Alanine; Antiparkinson Agents; Antiviral Agents; Computer Graphics; COVID-1 | 2020 |
Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
Topics: Alanine; Antiparkinson Agents; Behavioral Symptoms; Benzylamines; Cognition; Humans; Levodopa; Longi | 2022 |
Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Substitution; Female; Humans; Indans; Male; | 2021 |
Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies.
Topics: Alanine; Benzylamines; Dose-Response Relationship, Drug; Drug Discovery; Humans; Molecular Structure | 2021 |
New Drug Approved For Parkinson's Disease.
Topics: Alanine; Benzylamines; Contraindications, Drug; Drug Approval; Drug Labeling; Drug Therapy, Combinat | 2017 |
Hypersexuality Possibly Associated With Safinamide.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Disruptive, Impulse Control, and Conduct Disorder | 2017 |
Safinamide (Xadago) for Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Monoamine Oxidase Inhibitors; Motor Activity; P | 2017 |
[Safinamide from daily clinical practice: first clinical steps].
Topics: Adult; Aged; Aged, 80 and over; Alanine; Benzylamines; Female; Humans; Male; Middle Aged; Parkinson | 2017 |
Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients.
Topics: Alanine; Benzylamines; Female; Humans; Male; Middle Aged; Parkinson Disease; Restless Legs Syndrome; | 2018 |
Real life evaluation of safinamide effectiveness in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose | 2018 |
Serum metabolomics study in a group of Parkinson's disease patients from northern India.
Topics: Aged; Alanine; Female; Glutamine; Histidine; Humans; India; Isoleucine; Male; Metabolomics; Middle A | 2018 |
Effects of Ginkgo Biloba Extract on A53T α-Synuclein Transgenic Mouse Models of Parkinson's Disease.
Topics: Alanine; alpha-Synuclein; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Plasma Mem | 2018 |
A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
Topics: Alanine; alpha-Synuclein; Animals; Calcium-Binding Proteins; Disease Models, Animal; Endopeptidase K | 2018 |
Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Indans; Male; Middle Aged; Parkin | 2018 |
[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Disability Evaluation; | 2018 |
123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
Topics: Adult; Alanine; alpha-Synuclein; Cognition Disorders; Cohort Studies; Corpus Striatum; Dopamine; Fem | 2018 |
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopam | 2018 |
Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Male; Parkinson Disease; Retrospe | 2019 |
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Female; Humans; Indans | 2019 |
The role of the Ala746Thr variant in the ATP13A2 gene among Chinese patients with Parkinson's disease.
Topics: Age of Onset; Alanine; Asian People; Genetic Predisposition to Disease; Hong Kong; Humans; Middle Ag | 2013 |
Lack of association between the LRRK2 A419V variant and Asian Parkinson's disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Case-Control Studies; China; Cohort Studies; Cy | 2013 |
Substitution p.A350V in Na⁺/Mg²⁺ exchanger SLC41A1, potentially associated with Parkinson's disease, is a gain-of-function mutation.
Topics: Alanine; Amino Acid Substitution; Cation Transport Proteins; Cations, Divalent; Cations, Monovalent; | 2013 |
Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3.
Topics: 14-3-3 Proteins; Alanine; Animals; Binding Sites; Chlorocebus aethiops; COS Cells; Cyclic AMP-Depend | 2014 |
Dynamic Changes in Striatal mGluR1 But Not mGluR5 during Pathological Progression of Parkinson's Disease in Human Alpha-Synuclein A53T Transgenic Rats: A Multi-PET Imaging Study.
Topics: Alanine; alpha-Synuclein; Animals; Corpus Striatum; Disease Models, Animal; Disease Progression; Exc | 2016 |
Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties.
Topics: Alanine; alpha-Synuclein; Amino Acid Substitution; Amyloid; Circular Dichroism; Humans; Hydrophobic | 2008 |
Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Asian People; DNA Mutational Analysis; Exons; F | 2008 |
Selective noradrenergic vulnerability in α-synuclein transgenic mice.
Topics: Alanine; alpha-Synuclein; Animals; Disease Models, Animal; Humans; Mice; Mice, Inbred C3H; Mice, Inb | 2010 |
Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease.
Topics: Alanine; alpha-Synuclein; Animals; Aspartic Acid; Basal Ganglia; Cell Count; Dependovirus; Disease M | 2009 |
ATP13A2 G2236A variant is rare in patients with early-onset Parkinson's disease and familial Parkinson's disease from Mainland China.
Topics: Age of Onset; Alanine; China; DNA Mutational Analysis; Glycine; Humans; Parkinson Disease; Polymorph | 2010 |
Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy.
Topics: Alanine; alpha-Synuclein; Genetic Variation; Glutamic Acid; Humans; Lysine; Magnetic Resonance Spect | 2010 |
Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Biomarkers; Case | 2010 |
A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate, a new anti-Parkinson drug.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Calibration; Cellulose; Chromatography, High Pressure L | 2011 |
Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson's disease in Sardinia.
Topics: Aged; Alanine; Amino Acid Substitution; Case-Control Studies; Cohort Studies; DNA Mutational Analysi | 2011 |
Polymorphic Ala-allele carriers at residue 1170 of HER2 associated with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Alleles; Cell Survival; Dopamine; Female; Heterozygote; Hum | 2013 |
Mitochondrial DNA A4336G mutation in Alzheimer's and Parkinson's diseases.
Topics: Aged; Alanine; Alzheimer Disease; Case-Control Studies; DNA, Mitochondrial; Female; Glycine; Humans; | 2002 |
Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece.
Topics: Age of Onset; Aged; Aged, 80 and over; Alanine; alpha-Synuclein; DNA Mutational Analysis; Family Hea | 2003 |
Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein.
Topics: Alanine; alpha-Synuclein; Humans; Lipid Metabolism; Liposomes; Micelles; Mutation, Missense; Nerve T | 2004 |
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Topics: Alanine; alpha-Synuclein; Animals; Brain; Disease Models, Animal; Dopamine; Female; Gene Expression; | 2004 |
Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background.
Topics: Age Factors; Alanine; alpha-Synuclein; Animals; Behavior, Animal; Blotting, Western; Disease Models, | 2005 |
Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein.
Topics: Age Factors; Alanine; alpha-Synuclein; Amino Acid Substitution; Animals; Antibodies, Monoclonal; Blo | 2005 |
Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Topics: Alanine; alpha-Synuclein; Animals; Brain; Disease Models, Animal; Energy Metabolism; Mice; Mice, Inb | 2005 |
Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants.
Topics: Alanine; alpha-Synuclein; Amino Acid Sequence; Humans; Kinetics; Magnetic Resonance Spectroscopy; Mi | 2005 |
Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.
Topics: Alanine; alpha-Synuclein; Animals; Brain Stem; Cell Death; DNA Damage; Humans; Mice; Mice, Transgeni | 2006 |
Parkinson syndrome, neuropathy, and myopathy caused by the mutation A8344G (MERRF) in tRNALys.
Topics: Aged; Alanine; Amino Acid Substitution; Glycine; Humans; Male; MERRF Syndrome; Muscle, Skeletal; Mus | 2007 |
The Ala53Thr mutation in the alpha-synuclein gene in a Korean family with Parkinson disease.
Topics: Adult; Age of Onset; Alanine; alpha-Synuclein; Amino Acid Substitution; Family; Haplotypes; Humans; | 2007 |
On the oligomeric state of DJ-1 protein and its mutants associated with Parkinson Disease. A combined computational and in vitro study.
Topics: Alanine; Cell Line; Cross-Linking Reagents; Crystallography, X-Ray; Dimerization; Humans; In Vitro T | 2007 |
Effects of tyrosine administration on serum biopterin in normal controls and patients with Parkinson's disease.
Topics: Administration, Oral; Adrenal Glands; Alanine; Animals; Biopterins; Corpus Striatum; Humans; Injecti | 1983 |
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.
Topics: Alanine; alpha-Synuclein; Amino Acid Sequence; Base Sequence; Female; Humans; Male; Nerve Tissue Pro | 1998 |
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Topics: Age of Onset; Alanine; alpha-Synuclein; Amino Acid Substitution; Circular Dichroism; Humans; Lewy Bo | 1998 |
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Topics: Alanine; alpha-Synuclein; Amino Acid Sequence; Amyloid; Benzothiazoles; Binding Sites; Brain; Circul | 2000 |
Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells.
Topics: Alanine; alpha-Synuclein; Amino Acid Substitution; Animals; Cell Line; Cysteine Endopeptidases; Huma | 2000 |
Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
Topics: Alanine; alpha-Synuclein; Amyloid; Animals; Chromatography, Gel; Humans; Mice; Microscopy, Atomic Fo | 2000 |
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
Topics: Alanine; alpha-Synuclein; Animals; Humans; Mice; Mice, Transgenic; Mutation; Nerve Tissue Proteins; | 2002 |